-
1 Comment
Nordic Nanovector ASA is currently in a long term uptrend where the price is trading 4.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Nordic Nanovector ASA's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 19.8% to $-111M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.3% to $-65M since the same quarter in the previous year.
Based on the above factors, Nordic Nanovector ASA gets an overall score of 4/5.
| Industry | Biotechnology |
|---|---|
| Sector | Healthcare |
| ISIN | NO0010597883 |
| CurrencyCode | EUR |
| Exchange | F |
| Beta | 1.61 |
|---|---|
| Dividend Yield | 0.0% |
| Target Price | None |
| PE Ratio | None |
| Market Cap | 9M |
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 8NN.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
